Tesi etd-05122023-123117
Link copiato negli appunti
Tipo di tesi
Corso Ordinario Ciclo Unico 6 Anni
Autore
PARDOSSI, SIMONE
URN
etd-05122023-123117
Titolo
Breaking Through the Barriers of Treatment-Resistant Depression: A Multi-Dimensional and Symptom-Based Examination of the Effectiveness of Ketamine and Esketamine Therapies
Struttura
Cl. Sc. Sperimentali - Medicina
Corso di studi
SCIENZE MEDICHE - SCIENZE MEDICHE
Commissione
relatore Prof. EMDIN, MICHELE
Relatore Prof. FAGIOLINI, ANDREA
Presidente Prof. PASSINO, CLAUDIO
Membro Prof.ssa ANGELONI, DEBORA
Membro Dott. VERGARO, GIUSEPPE
Membro Prof. LIONETTI, VINCENZO
Membro Prof. GIANNONI, ALBERTO
Membro Prof. AIMO, ALBERTO
Relatore Prof. FAGIOLINI, ANDREA
Presidente Prof. PASSINO, CLAUDIO
Membro Prof.ssa ANGELONI, DEBORA
Membro Dott. VERGARO, GIUSEPPE
Membro Prof. LIONETTI, VINCENZO
Membro Prof. GIANNONI, ALBERTO
Membro Prof. AIMO, ALBERTO
Parole chiave
- DIMENSIONAL APPROACH
- GLUTAMATE
- MIXED SYMPTOMS
- MOOD SPECTRUM
- NOVEL THERAPIES FOR DEPRESSION
Data inizio appello
19/06/2023;
Disponibilità
parziale
Riassunto analitico
Treatment-Resistant Depression (TRD) is characterized by the failure of two or more antidepressant therapies (adjusted for dosage and duration). Among the therapeutic options for TRD, Ketamine has emerged as a rapid and effective treatment. Esketamine has gained approval specifically for the management of TRD.
In our retrospective-observational study, we focused on 53 patients diagnosed with TRD who were treated either with Esketamine or Ketamine. Our evaluation encompassed various aspects such as depressive symptomatology, manic/hypomanic symptoms, and potential side effects. Remarkably, we observed a significant reduction in depressive symptoms, including those associated with "mixed symptoms" such as inner tension. Both Esketamine and Ketamine exhibited favorable safety profiles and were well-tolerated by the patients. It is noteworthy that despite all the patients were diagnosed with TRD, they exhibited diverse symptoms, including mixed symptoms. Consequently, our study underscores the importance of adopting a multidimensional approach and considering individual symptoms when dealing with TRD.
In our retrospective-observational study, we focused on 53 patients diagnosed with TRD who were treated either with Esketamine or Ketamine. Our evaluation encompassed various aspects such as depressive symptomatology, manic/hypomanic symptoms, and potential side effects. Remarkably, we observed a significant reduction in depressive symptoms, including those associated with "mixed symptoms" such as inner tension. Both Esketamine and Ketamine exhibited favorable safety profiles and were well-tolerated by the patients. It is noteworthy that despite all the patients were diagnosed with TRD, they exhibited diverse symptoms, including mixed symptoms. Consequently, our study underscores the importance of adopting a multidimensional approach and considering individual symptoms when dealing with TRD.
File
| Nome file | Dimensione |
|---|---|
Ci sono 1 file riservati su richiesta dell'autore. |
|